UPDATE: Supply of pediatric cancer drug catching up
New shipments went out of a pediatric cancer drug recently in short supply, and it appears northeast Kansas facilities are back to treating patients as usual.
One of only two U.S. manufacturers of Vincristine stopped making it in July. The remaining provider, Pfizer, ramped up production, but warned it might not be able to keep up with demand.
By mid-October, a shortage was listed on the FDA's web site. The company said it may not fully meet demand until January.
The alert led many facilities across the country to reserve the drug for newly diagnosed children. Vincristine is part of nearly every drug combination used for pediatric and young adult cancer patients all the way through their maintenance phases.
This week, The FDA posted an update that late-October deliveries were received, and the drug is once again available to order.
Stormont Vail in Topeka confirmed it received a new shipment, and does not anticipate having to change any processes. They had said two week ago that, if the shortage had stretched into December, it may have had to make changes.
Children's Mercy in Kansas City says it received two shipments last week, and has lifted its restrictions on Vincristine dosing.